BILLERICA, Mass.--(BUSINESS WIRE)--May. 29, 2009--
Bruker Daltonics announced today that the Rapid Structure
Characterization Laboratory (RSCL) of the Schering-Plough Research
Institute (SPRI) has selected the new solariX™
FTMS platform from Bruker Daltonics as a cutting-edge tool for
structural characterization and purity assessment of pharmaceuticals
under development at SPRI. The solariX, with its expansive
capabilities, is ideally suited as the ultimate analysis platform to
address the rigorous challenges of these application areas in
pharmaceutical development.
Bruker Daltonics explained that the RSCL can be tasked with solving some
of the most difficult chemical structure problems encountered during
drug development, as well as many day-to-day applications, that
companies have for structural characterization of chemical compounds.
Dr. Gary Martin, Distinguished Fellow at Schering Plough and the leader
of the RSCL, commented: “The chemical formula provided by the solariX
platform for both the complete unknown, as well as pieces of the unknown
compound from MSn, is pivotal information that can complement
the information derived from NMR spectroscopy. Combining these data can
speed the solving of complex structural problems. We look forward to
using solariX in our work.”
Dr. Paul Speir, Vice President for FTMS at Bruker Daltonics, stated:
“Our solariX FTMS platform offers unmatched mass
resolution and flexibility, a wide variety of ionization techniques, the
capability to perform MSn experiments with accurate mass
measurement at each stage, and is even capable of ion-molecule
reactions. All of these capabilities can be useful in solving the
extremely difficult structural characterization problems that
pharmaceutical scientists routinely encounter.”
For further product information, please visit www.bdal.com/solariX.
ABOUT BRUKER DALTONICS
For more information about Bruker Daltonics and Bruker Corporation
(NASDAQ: BRKR), please visit www.bdal.com
and www.bruker.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5975532&lang=en
Source: Bruker Daltonics
Bruker Daltonics
Dr. Paul Speir, +1 978-663-3660
jps@bdal.com